Radiologically Isolated Syndrome
14
4
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
7%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (14)
Diagnostic Value of eVOG
The Italian Multiple Sclerosis and Related Disorders Register
Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients
Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
MS-ResearchBiomarkerS
Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome
Risk Factors in Early Multiple Sclerosis
RIS International Cohort
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography